MEDICINE AND MATERIALS

Volume 4, Issue 4, 2024: 181-186 | ISSN: 2784 – 1499 & e-ISSN: 2784 – 1537

DOI: 10.36868/MEDMATER.2024.04.04.181 | www.medicineandmaterials.com |

NANOTECHNOLOGY IN UROLOGY, A NEW HORIZON IN REGENERATIVE AND ONCOLOGICAL TREATMENTS

Gabriel Giani CONDURACHE[1] , Ion CIUCĂ[2,*] , Mocanu Costel IULIAN[1]

[1] Dunarea de Jos University of Galati, Facultatea de Medicina si Farmacie, Str. Al. I. Cuza Nr. 35, Galati, Romania.
[2] Materials Science and Engineering Faculty in University Politehnica of Bucharest, Romania.

Abstract

Nanobiomaterials have opened new horizons in urology, offering innovative solutions for regenerative and oncological treatments. These materials, due to their unique properties such as nanometer dimensions, biocompatibility, and functionalization capacity, have the potential to significantly improve the efficiency and precision of clinical interventions. In urological regeneration, nanostructures are used to design scaffolds that facilitate cell proliferation and tissue reconstruction, being applied in defects of the bladder, urethra, and kidney tissue. Also, in urological oncology, nano-biomaterials play a central role in targeted drug delivery, photothermal, and photodynamic therapy, as well as in early diagnosis through advanced imaging. However, the use of nanomaterials comes with significant challenges. Technical aspects include stability in the biological environment and limitations in synthesis and functionalization. Clinically, adverse reactions and toxicity require increased attention, and the scalability of production is a major barrier to widespread application. Also, the high costs and ethical concerns related to the use of nanotechnology in medicine limit the accessibility of these innovations. Despite these challenges, continued advances in research promise to completely transform urology, paving the way for personalized and more effective treatments.

Keywords: nanobiomaterials, urology, regeneration, oncology, targeted therapy, early diagnosis.

Introduction

Nanobiomaterials are an emerging category of nanoscale materials (1-100 nm) with extensive applications in biomedicine due to their unique properties, such as large specific surface area, increased biocompatibility, and the ability to selectively interact with biological systems. These characteristics give them an essential role in the advancement of modern treatments, including tissue regeneration and personalized therapies in oncology [1-4].

In the context of urology, a field that integrates surgery, oncology and regenerative medicine, the need for effective and minimally invasive solutions is growing. Urological diseases such as prostate cancer, bladder cancer or chronic kidney failure present considerable therapeutic challenges. Current treatments, while effective in certain cases, are often limited by significant side effects, prolonged recoveries, or high costs. In this context, nanobiomaterials offer a promising alternative, due to their ability to optimize tissue regeneration and improve oncology treatments through targeted delivery of advanced drugs and therapies such as photothermal or photodynamics [1,3,4].

Nanotechnology plays a fundamental role in revolutionizing urological treatments. In regeneration, nanostructures provide an ideal platform for stem cell proliferation and optimal integration of the reconstructed tissue. In oncology, functionalized nanoparticles allow for early

Corresponding author: Ion.ciuca11@gmail.com

detection of tumors and controlled drug delivery, which reduces toxicity and increases the chances of survival [3-5].

By integrating nanomaterials into clinical practice, urology can move from conventional therapies to personalized, minimally invasive, and highly effective treatments. In conclusion, this interdisciplinary field has the potential to redefine the standards of care for patients with urological conditions, paving the way for more accurate and sustainable medicine [3-6].

Classification of nanomaterials used in urology

Nanobiomaterials used in urology can be classified according to chemical composition, specific applications, and the combination of multiple materials to achieve improved performance [4-6].

Gold, silver, and iron oxide nanoparticles are intensively studied due to their unique properties. Gold nanoparticles are used in photothermal therapies to destroy tumor cells in prostate and bladder cancer, generating heat under the action of a laser, without affecting healthy tissues. Silver nanoparticles, known for their antimicrobial properties, are used to prevent infections associated with medical devices such as urinary catheters. Iron oxide has important applications in magnetic resonance imaging (MRI), providing a valuable tool for the early diagnosis of urological tumors [4-7].

Zinc oxide (ZnO) and titanium oxide (TiO_2) are two of the most widely used ceramic nanoparticles due to their biocompatibility and stability. ZnO exhibits anticancer effects by generating oxidative stress in tumor cells, while TiO_2 is used in cancer phototherapy, generating reactive oxygen species (ROS) under the action of UV light, which destroys malignant cells [5-8].

Polymers are used to manufacture scaffolding and drug delivery systems. Natural polymers such as chitozan, derived from crustacean chitin, are biocompatible, biodegradable, and exhibit antimicrobial properties. Synthetic polymers, such as polylactide (PLA) and polyglycolide (PGA), are commonly used to create biodegradable structures that promote urethral tissue or bladder regeneration [3,5-8].

Nanocomposites are combinations of materials, such as polymers with metallic or ceramic nanoparticles, to achieve improved mechanical properties and antibacterial effects. Nanostructured hydrogels are frequently used in regeneration and controlled drug delivery, having the ability to respond to stimuli such as pH or temperature, making them extremely versatile in urology [7-11].

Table 1. Classification of nanobiomaterials in urology [7-11].

Category	Examples/Materials	Applications
Metallic nanoparticles	Gold, silver, iron oxide	Photothermal therapies, advanced imaging, antimicrobial effect
Ceramic nanoparticles	Zinc oxide (ZnO), titanium oxide (TiO_2)	Photodynamic therapy, destruction of tumor cells
Natural and synthetic polymers	Chitosan, polylactide (PLA), polyglycolide (PGA)	Scaffolds for tissue regeneration, drug delivery
Biomaterials for tissue regeneration	Nanostructured hydrogels, electrospun nanofibers	Bladder and urethral tissue regeneration
Biomaterials for cancer therapies	Functionalized nanoparticles, gold, iron oxide	Targeted drug delivery, imaging, and photothermal therapy
Nanocomposites and hydrogels	Polymeric nanocomposites, functionalized hydrogels	Tissue regeneration, controlled drug release

Applicability in urological regeneration

Nanobiomaterials play an essential role in urological regeneration, providing innovative solutions for the repair of bladder, urethral and renal defects, as well as for treatments for urinary incontinence. These materials, due to their unique properties, can stimulate tissue regeneration by creating favorable environments for cell proliferation [8-12].

Bladder and urethral defects are common challenges in urology, often occurring as a result of trauma, birth defects, or tumors. Nanostructure-based scaffolds are used to replace and regenerate these delicate structures. For example, electrospun nanofibers made from biodegradable polymers such as polylactide (PLA) and chitosan are designed to mimic the natural extracellular matrix, facilitating the attachment, proliferation, and differentiation of epithelial and smooth muscle cells [9-12].

Preclinical studies have demonstrated the success of these scaffolds in functional bladder regeneration in animal models. A notable example is the use of nanostructured collagen-based scaffolds in combination with stem cells, which have been shown to restore bladder capacity and reduce the risk of scar tissue formation. Early clinical trials have also shown promising results, suggesting the viability of these technologies in clinical practice [8-13].

Urinary incontinence, a common condition that affects quality of life, can be treated by injecting biomaterials that act as volumizing agents to support the urethral sphincter. Nanostructured hydrogels, due to their biocompatibility properties and ability to adapt to the biological environment, are used to provide effective and minimally invasive solutions. These materials not only improve the function of the sphincter, but also stimulate local tissue regeneration [8,10-13].

The role of nanobiomaterials in urological oncology

Nanobiomaterials have brought significant advances in urological oncology, especially in early diagnosis and personalized treatments for prostate and bladder cancers. Due to their nanoscale size and ability to selectively interact with tumor tissues, these materials contribute to improving therapeutic efficacy and reducing systemic adverse effects [8,10-15].

In targeted drug therapy, functionalized nanoparticles are used to deliver chemotherapeutic agents directly to tumor cells. In prostate cancer, gold nanoparticles coated with specific ligands enable precise transport of docetaxel, reducing toxicity and increasing treatment efficiency. Similarly, functionalized iron oxide nanoparticles are used in the treatment of bladder cancer, allowing both controlled drug delivery and progress monitoring through MRI imaging [11-15].

Photodynamic and photothermal therapy are other important applications. In photodynamic therapy, light-activated nanoparticles generate reactive oxygen species, which destroy tumor cells. Photothermal therapy involves the use of gold nanoparticles to convert light energy into heat, selectively eliminating cancer cells [12-16].

In early diagnosis, functionalized nanoparticles are used as contrast agents in advanced imaging (MRI, CT). For example, iron oxide and gold nanoparticles can detect small tumors, providing precise information for personalized treatments [11,14-17].

Through these applications, nanobiomaterials open up new perspectives in urological oncology, revolutionizing therapeutic approaches and contributing to the significant improvement of patients' quality of life [15-18].

Challenges and limitations

Nanobiomaterials offer significant benefits in urology, but their use faces numerous challenges and limitations related to technical, clinical, economic and ethical aspects. These barriers need to be addressed to ensure the effective transition from research to large-scale clinical use [17-19].

Table 2. Further expanded challenges and limitations of nanobiomaterials [11-20].

Category	Key issues	Implications
Technical aspects	Complex manufacturing processes requiring specialized equipment, difficulty in achieving reproducibility for large-scale production.	Slows the development and clinical translation of nanotechnology, increases production costs and limits availability.
Material design and synthesis	High precision required in nanoparticle functionalization, difficulty in ensuring compatibility with biological systems.	Reduces success rates in targeting specific biological pathways, necessitates additional investment in research.
Stability and degradation	Instability of nanomaterials under physiological conditions, risk of degradation leading to loss of therapeutic effectiveness.	May reduce effectiveness in clinical environments, requires strategies to enhance stability and minimize degradation.
Clinical aspects	Potential toxicity and long-term effects on healthy tissues, immune system reactions and inflammatory responses.	Poses risks to patient safety, requires careful evaluation of risk-benefit ratios in clinical trials.
Patient safety	Unpredictable interactions with biological systems, necessity for extensive preclinical and clinical testing.	Delays in regulatory approvals due to safety concerns, increased scrutiny for long-term patient outcomes.
Scalability and Standardization	Challenges in mass production while maintaining quality, lack of standardized manufacturing and clinical protocols.	Restricts scalability of promising technologies, hinders widespread adoption in clinical practice.
Regulation and environmental impact	Potential environmental hazards from nanomaterial waste, need for clear and enforceable regulatory guidelines.	Introduces potential risks to ecosystems, necessitates interdisciplinary collaboration for sustainable practices.

Clinical aspects include risks of toxicity and adverse reactions. The nanoparticles can interact with the immune system or accumulate toxicity in tissues, which can lead to serious side effects. In addition, the scalability of production remains a significant problem, as current technologies do not allow for the economical and consistent manufacture of nanomaterials for large-scale use [13,18-21].

From an economic perspective, the high costs of research, development and production are a significant barrier to clinical implementation. Accessibility for patients, especially in low- and middle-income countries, is limited, raising issues of equity in healthcare. Ethical issues refer to possible unknown risks associated with the use of nanotechnology, as well as concerns about the privacy and safety of patient data in the case of nanomaterials used for diagnosis [18-21].

Conclusions

Nanobiomaterials represent an emerging field with huge potential in urology, transforming therapeutic approaches for tissue regeneration and oncology treatments. Their unique properties, such as biocompatibility, nanometer dimensions and functionalization capacity, allow the creation of customized, minimally invasive and effective solutions.

In urological regeneration, the use of nanostructured scaffolds and hydrogelia promotes cell proliferation and reconstruction of affected tissues, providing a viable alternative for bladder, urethral and renal defects. In oncology, the application of nanoparticles in targeted drug therapy, photothermy, and early diagnosis has shown promising results in increasing treatment efficiency and reducing adverse effects.

However, the implementation of nanobiomaterials in clinical practice faces significant challenges. Technical limitations, such as stability in the biological environment and the complexity of synthesis, together with clinical and economic aspects, such as toxicity, high costs and scalability of production, remain important barriers. Also, ethical concerns about the use of nanotechnology require clear regulation.

Despite these limitations, rapid advances in research and integration with advanced technologies such as 3D bioprinting and artificial intelligence offer tremendous opportunities. Nanobiomaterials have the potential to revolutionize urology, contributing to the development of safer, more precise and more accessible treatments, significantly improving the quality of life of patients.

Bibliography

1. Wang X, Yang L, Chen ZG, Shin DM. *Application of nanotechnology in cancer therapy and imaging.* **CA Cancer. J Clin**. 2008. 58, 97–110. doi: 10.3322/CA.2007.0003.
2. Baban DF, Seymour LW. *Control of tumour vascular permeability.* **Adv Drug Deliv Rev**. 1998. 34, 109–19. doi: 10.1016/s0169-409x(98)00003-9.
3. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al *Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment.* **Proc Natl Acad Sci U S A**. 1998. 95, 4607–12. doi: 10.1073/pnas.95.8.4607.
4. Wunderbaldinger P, Josephson L, Bremer C, Moore A, Weissleder R. *Detection of lymph node metastases by contrast-enhanced MRI in an experimental model***. Magn Reson Med.** 2002. 47, 292–7. doi: 10.1002/mrm.10068.
5. Perrault SD, Chan WC. *In vivo assembly of nanoparticle components to improve targeted cancer imaging.* **Proc Natl Acad Sci U S A.** 2010. 107:11194–9. doi: 10.1073/pnas.1001367107.
6. Guimares AR, Tabatabei S, Dahl D, McDougal WS, Weissleder R, Harisinghani MG. *Pilot study evaluating use of lymphotropic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer.* **Urology**. 2008. 71. 708–12
7. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al *Noninvasive detection of clinically occult lymph-node metastases in prostate cancer***. N Engl J Med**. 2003. 348, 2491–9. doi: 10.1056/NEJMoa022749.
8. Harisinghani MG, Saksena M, Ross RW, Tabatabaei S, Dahl D, McDougal S, et al *A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: A new method for noninvasive lymph node evaluation.* **Urology**. 2005. 66. 1066–71. doi: 10.1016/j.urology.2005.05.049.
9. Warncke SH, Mattei A, Fuechsel FG, Z’Brun S, Krause T, Studer UE. *Detection rate and operating time required for gamma probe-guided sentinel lymph node resection after injection of technetium-99m nanocolloid into the prostate with and without preoperative imaging*. **Eur Urol**. 2007. 52, 126–32. doi: 10.1016/j.eururo.2007.01.050.
10. Shi C, Zhu Y, Cerwinka WH, Zhau HE, Marshall FF, Simons JW, et al *Quantum dots: Emerging applications in urologic oncology*. **Urol Oncol**. 2008.26,86–92. doi: 10.1016/j.urolonc.2007.03.018

11. Ma Q, Lin ZH, Yang N, Li Y, Su XG. *A novel carboxymethyl chitosan-quantum dot-based intracellular probe for Zn2+ion sensing in prostate cancer cells.* **Acta Biomater**. 2014. 10, 868–74. doi: 10.1016/j.actbio.2013.10.039.
12. Gao X, Cui Y, Levenson RM, Chung LW, Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. **Nat Biotechnol**. 2004. 22, 969–76. doi: 10.1038/nbt994.
13. Thaxton CS, Elghanian R, Thomas AD, Stoeva SI, Lee JS, Smith ND, et al *Nanoparticle-based bio-barcode assay redefines "undetectable" PSA and biochemical recurrence after radical prostatectomy.* **Proc Natl Acad Sci U S A.** 2009. 106, 18437–42. doi: 10.1073/pnas.0904719106.
14. Wu G, Datar RH, Hansen KM, Thundat T, Cote RJ, Majumdar A. *Bioassay of prostate-specific antigen (PSA) using microcantilevers.* **Nat Biotechnol**. 2001. 19, 856–60. doi: 10.1038/nbt0901-856.
15. Grubisha DS, Lipert RJ, Park HY, Driskell J, Porter MD. *Femtomolar detection of prostate-specific antigen: An immunoassay based on surface-enhanced Raman scattering and immunogold labels.* **Anal Chem.** 2003. 75, 5936–43. doi: 10.1021/ac034356f.
16. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. *Nanocarriers as an emerging platform for cancer therapy*. **Nat Nanotechnol**. 2007.2, 751–60
17. Sahoo SK, Ma W, Labhasetwar V. *Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer***. Int J Cancer**. 2004. 112, 335–40. doi: 10.1002/ijc.20405.
18. Lu Z, Yeh TK, Tsai M, Au JL, Wientjes MG. *Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy.* **Clin Cancer Res**. 2004. 10, 7677–84. doi: 10.1158/1078-0432.CCR-04-1443.
19. Derycke AS, Kamuhabwa A, Gijsens A, Roskams T, De Vos D, Kasran A, et al *Transferrin-conjugated liposome targeting of photosensitizer AlPcS4 to rat bladder carcinoma cells***. J Natl Cancer Inst.** 2004. 96, 1620–30. doi: 10.1093/jnci/djh314.
20. Martin DT, Hoimes CJ, Kaimakliotis HZ, Cheng CJ, Zhang K, Liu J, et al *Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer*. **Nanomedicine**. 2013. 9, 1124–34. doi: 10.1016/j.nano.2013.05.017.
21. Winquist E, Ernst DS, Jonker D, Moore MJ, Segal R, Lockwood G, et al *Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract.* **Eur J Cancer**. 2003. 39, 1866–71. doi: 10.1016/s0959-8049(03)00358-7

Received: July 20, 2024
Accepted: November 21, 2024